Deng, Xuewen
Terunuma, Hiroshi
Article History
Received: 1 February 2024
Accepted: 21 June 2024
First Online: 26 June 2024
Declarations
:
: Not applicable.
: Not applicable.
: X.D. and H.T. hold patents for feeder-cell-free NK cell expansion culture technology, are stockholders and employed by the company of Biotherapy Institution of Japan Inc., a biotech startup company developing NK-cell-based immunotherapy and Mesenchymal Stromal Cell (MSC)-based products, such as adipose MSCs, and MSC-derived conditioned medium (CM) concentrates and extracellular vesicle (EV) isolates (StemSupĀ®) for clinical research.